These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10549714)

  • 1. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis.
    Kaiser B; Kirchmaier CM; Breddin HK; Fu K; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():35-42. PubMed ID: 10549714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins: are they different?
    Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
    Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
    Jeske W; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():27-33. PubMed ID: 10549713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are the available low-molecular-weight heparin preparations the same?
    Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
    Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparins in the outpatient management of venous thromboembolism.
    Bick RL
    Semin Thromb Hemost; 1999; 25 Suppl 3():97-9. PubMed ID: 10549723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparins: background and pharmacology.
    Morris TA
    Semin Respir Crit Care Med; 2000; 21(6):537-46. PubMed ID: 16088762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
    Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
    Semin Thromb Hemost; 1995; 21(2):212-27. PubMed ID: 7660144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis.
    Davidson BL
    Semin Thromb Hemost; 1999; 25 Suppl 3():107-12. PubMed ID: 10549725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
    Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
    J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
    Haas S
    Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin and low-molecular weight heparins in thrombosis and beyond.
    Mousa SA
    Methods Mol Biol; 2010; 663():109-32. PubMed ID: 20617415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.